Contractor Dorizoe will help facilitate accelerated development of over 20 of Baxter’s generic molecule products, including anti-infectives, oncolytics and cardiovascular medicines.
The US-headquartered firm estimates the global sterile generic injectables segment, which it says is worth over $40bn (€35.7bn), grows by approximately 10 percent annually.
Baxter will maintain manufacturing and commercialisation rights.
The firm did not disclose financial terms of the agreement.
An injectables trend
The partnership follows Baxter’s agreement with ScinoPharm announced earlier this year, to develop, manufacture and commercialise up to 20 injectable cancer drugs at facilities in Germany and Taiwan.
Last year Baxter agreed to purchase India-based Claris Lifesciences for $625m (€598). The acquisition, which includes three facilities in Ahmedabad, India, and a pipeline of generic injectable drug candidates, is expected to close later this year.